Selective estrogen receptor modulators (SERMs) appear to reduce the incidence of breast cancer in high-risk women. Five years of tamoxifen administration after the diagnosis of breast cancer results in a 50% reduction in the incidence of contralateral breast cancer. This reduction is maintained for 5 years after therapy is discontinued. The Study of Tamoxifen And Raloxifene (STAR), presently ongoing, will address the questions of breast cancer prevention, risk of endometrial cancer, the incidence of bone fractures, and coronary artery disease in women treated with these SERMs.
1. Jordan VC, ed. Tamoxifen for the treatment and prevention of breast cancer. New York, NY: PRR, 1998.
2.
2. Delmas PD, Bjornason NH, Mitlak BH, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations and uterine endometrium in postmenopausal women. N Engl J Med1997;337:1641-1647.
3.
3. Jordan VC, Glusman JE, Eckert S, et al. Incident primary breast cancer are reduced by raloxifene: Integrated data from multicenter double blind, randomized trials in 12,000 postmenopausal women. Proc Am Soc Clin Oncol (LA)1998;17:(abstract):466-466.
4.
4. Lerner LJ, Jordan VC. Development of antiestrogens and their use in breast cancer. Eighth Cain Memorial Award Lecture Cancer Res1990;50:4177-4189.
5.
5. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: An overview of randomized clinical trials. Lancet1998;351:1451-1467.
6.
6. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: Report of the NSABP P-1 study. J Natl Cancer Inst1998;90:1371-1388.
7.
7. Jordan VC, Morrow M. Tamosifen, raloxifene and the prevention of breast cancer. Endocrine Rev1990;20:253-278.
8.
8. Jordan VC. Designer estrogens. Sci Am1998;279:60-67.
